These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33016303)

  • 21. Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells.
    Kell SA; Kachura MA; Renn A; Traquina P; Coffman RL; Campbell JD
    Int Immunopharmacol; 2019 Jan; 66():296-308. PubMed ID: 30502651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity.
    Masuda Y; Nawa D; Nakayama Y; Konishi M; Nanba H
    J Leukoc Biol; 2015 Dec; 98(6):1015-25. PubMed ID: 26297795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.
    Chiang CY; Chen YJ; Wu CC; Liu SJ; Leng CH; Chen HW
    Front Immunol; 2018; 9():822. PubMed ID: 29755461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
    Karan D; Krieg AM; Lubaroff DM
    Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-adjuvanted nanovaccine for cancer immunotherapy: Role of lysosomal rupture-induced ROS in MHC class I antigen presentation.
    Wang C; Li P; Liu L; Pan H; Li H; Cai L; Ma Y
    Biomaterials; 2016 Feb; 79():88-100. PubMed ID: 26702587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Situ biomimetic Nanoformulation for metastatic cancer immunotherapy.
    Zhang X; Zhang Y; Zheng H; He Y; Jia H; Zhang L; Lin C; Chen S; Zheng J; Yang Q; Liu T; Pan X; Zhang H; Wang C; Ren L; Shan W
    Acta Biomater; 2021 Oct; 134():633-648. PubMed ID: 34329780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
    Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
    J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TLR ligands in the local treatment of established intracerebral murine gliomas.
    Grauer OM; Molling JW; Bennink E; Toonen LW; Sutmuller RP; Nierkens S; Adema GJ
    J Immunol; 2008 Nov; 181(10):6720-9. PubMed ID: 18981089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toll-like receptor 9 regulates tumor necrosis factor-alpha expression by different mechanisms. Implications for osteoclastogenesis.
    Amcheslavsky A; Zou W; Bar-Shavit Z
    J Biol Chem; 2004 Dec; 279(52):54039-45. PubMed ID: 15485822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Self-assembled nanovehicle-mediated co-encapsulation of inactivated EV71 virus and CpG oligonucleotides elicits potent anti-EV71 humoral and cellular immune protective responses.
    Liang H; Xiao X; Zhang X; Hu Q; Yang Y; Cen S; Deng X; Sheng W
    Biochem Biophys Res Commun; 2019 Apr; 511(2):253-259. PubMed ID: 30777330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanovaccine Incorporated with Hydroxychloroquine Enhances Antigen Cross-Presentation and Promotes Antitumor Immune Responses.
    Liu J; Liu X; Han Y; Zhang J; Liu D; Ma G; Li C; Liu L; Kong D
    ACS Appl Mater Interfaces; 2018 Sep; 10(37):30983-30993. PubMed ID: 30136844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Self-assembling CpG DNA nanoparticles for efficient antigen delivery and immunostimulation.
    Rattanakiat S; Nishikawa M; Takakura Y
    Eur J Pharm Sci; 2012 Sep; 47(2):352-8. PubMed ID: 22771546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced immune response to gastric cancer specific antigen Peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion.
    Shi R; Hong L; Wu D; Ning X; Chen Y; Lin T; Fan D; Wu K
    Cancer Biol Ther; 2005 Feb; 4(2):218-24. PubMed ID: 15753659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
    Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A self-designed CpG ODN enhanced the anti-melanoma effect of pimozide.
    Jia H; Guo J; Wang P; Sun K; Chen J; Ren W; Wei T; Yang Y; Li J; Liu X; Li R; Zhong J; Wang M; Tian Z; Feng Z; Zhao T
    Int Immunopharmacol; 2020 Jun; 83():106397. PubMed ID: 32220805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
    Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
    Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
    Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
    J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.